Form 8-K - Current report:
SEC Accession No. 0001213900-25-051750
Filing Date
2025-06-06
Accepted
2025-06-06 08:33:03
Documents
14
Period of Report
2025-06-05
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0244845-8k_cero.htm   iXBRL 8-K 32664
2 PRESS RELEASE DATED JUNE 6, 2025 ea024484501ex99-1_cero.htm EX-99.1 10316
  Complete submission text file 0001213900-25-051750.txt   260070

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20250605.xsd EX-101.SCH 3797
4 XBRL DEFINITION FILE cero-20250605_def.xml EX-101.DEF 26672
5 XBRL LABEL FILE cero-20250605_lab.xml EX-101.LAB 36816
6 XBRL PRESENTATION FILE cero-20250605_pre.xml EX-101.PRE 25296
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0244845-8k_cero_htm.xml XML 5942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251028969
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)